Nelfinavir induces necrosis of 3T3F44-2A adipocytes by oxidative stress

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 5, 2004, Pages 1556-1562

  Vincent, Stéphanie ^a   Tourniaire, Franck ^a   El Yazidi, Claire M ^a   Compe, Emmanuel ^b   Manches, Olivier ^c   Plannels, Richard ^a   Roche, Régis ^d,e  

^a INSERM   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c EFS   (France)

^d UNIVERSITÉ DE LA RÉUNION   (France)

^e INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Adipocytes; Ascorbate; Lipodystrophy; Necrosis; Nelfinavir; Oxidative stress

Indexed keywords

ASCORBIC ACID; HEME OXYGENASE 1; NELFINAVIR; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL LEVEL; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

3T3 CELLS; ADIPOCYTES; ANIMALS; APOPTOSIS; ASCORBIC ACID; CELL LINE; HEME OXYGENASE-1; HIV PROTEASE INHIBITORS; MICE; NECROSIS; NELFINAVIR; OXIDATIVE STRESS;

EID: 10644269509     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200412150-00003     Document Type: Article

References (44)

1. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin infect Dis. 2000;30(Suppl 1):S5-S14.
2. Shafer RW, Vuitton DA. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother. 1999;53:73-86.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733.
4. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
5. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
6. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
7. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883.
8. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
9. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
10. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:228-237.
11. Roche R, Poizot-Martin I, Yazidi CM, et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 2002;16:13-20.
12. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
13. Gagnon A, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet. 1998;352:1032.
14. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol. 2000;164:R7-R10.
15. Zhang B, MacNaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab. 1999;84:4274-4277.
16. Dowell P, Flexner C, Kwiterovich PO, et al. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 2000;275:41325-41332.
17. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378-1388.
18. Tran H, Robinson S, Mikhailenko I, et al. Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res. 2003;44:1859-1869.
19. Treluyer JM, Morini JP, Dimet J, et al. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2002;46:4009-4012.
20. Ben-Romano R, Rudich A, Torok D, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS. 2003;17:23-32.
21. Rudich A, Vanounou S, Riesenberg K, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3L1 adipocytes. Diabetes. 2001;50:1425-1431.
22. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-129.
23. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol. Chem. 2002;277:19247-19250.
24. Sarkissian G, Dace A, Mesmacque A, et al. A novel resistance to thyroid hormone associated with a new mutation (T329N) in the thyroid hormone receptor beta gene. Thyroid. 1999;9:165-171.
25. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
26. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:1026-1031.
27. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS. 2003;17:121-123.
28. Maher B, Alfirevic A, Vilar FJ, et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 2002;16:2013-2018.
29. Nerurkar PV, Shikuma CM, Nerurkar VR. Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy. Clin Biochem. 2001;34:519-529.
30. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
31. Qian H, Hausman DB, Compton MM, et al. TNF-alpha induces and insulin inhibits caspase 3-dependent adipocyte apoptosis. Biochem Biophys Res Commun. 2001;284:1176-1183.
32. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS. 1999;13:2261-2267.
33. Phenix BN, Lum JJ, Nie Z, et al. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood. 2001;98:1078-1085.
34. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 2000;16:559-567.
35. Ruan H, Hacohen N, Golub TR, et al. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes. 2002;51:1319-1336.
36. Prins JB, Niesler CU, Winterford CM, et al. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes. 1997;46:1939-1944.
37. Sewter CP, Digby JE, Blows F, et al. Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol. 1999;163:33-38.
38. Burlacu A, Jinga V, Gafencu AV, et al. Severity of oxidative stress generates different mechanisms of endothelial cell death. Cell Tissue Res. 2001;306:409-416.
39. Vile GF, Basu-Modak S, Waltner C, et al. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA. 1994;91:2607-2610.
40. Elbirt KK, Bonkovsky HL. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians. 1999;111:438-447.
41. Paulik MA. Report and abstracts of the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 13-15 September 2000, Toronto, Canada. Antivir Ther. 2000;5(Suppl 5):xv-xxiv,6.
42. Will Y, Kaetzel RS, Brown MK, et al. In vivo reversal of glutathione deficiency and susceptibility to in vivo dexamethasone-induced apoptosis by N-acetylcysteine and L-2-oxothiazolidine-4-carboxylic acid, but not ascorbic acid, in thymocytes from gamma-glutamyltranspeptidase-deficient knockout mice. Arch Biochem Biophys. 2002;397:399-406.
43. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552-565.
44. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002;110:1389-1398.